Lekoklar Mite

Clarithromycin, the active ingredient in Lekoklar Mite, is a macrolide antibiotic presented as an oral formulation for systemic use. It treats a range of bacterial infections, including respiratory, sinus, skin, and gastrointestinal infections, and is commonly prescribed for adults and children under medical supervision, following susceptibility testing when appropriate, to ensure optimal outcome and minimize resistance.

GNH USA supplies Lekoklar Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for timely delivery across global markets.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections affecting the respiratory, sinus, skin, and gastrointestinal systems.

- Community-acquired pneumonia: reduces bacterial load and improves clinical symptoms, leading to faster recovery. - Acute bacterial sinusitis: alleviates sinus inflammation and clears infection, restoring normal sinus function. - Skin and soft tissue infections: eradicates causative bacteria, promoting healing of cellulitis, abscesses, and wound infections. - Helicobacter pylori eradication: part of combination therapy to eliminate H. pylori, aiding ulcer healing and reducing recurrence.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset occurring shortly after the dose, often transient. - Diarrhea: loose, watery stools that are usually self‑limiting and resolve without intervention. - Abdominal pain: cramping or discomfort in the abdomen, typically mild to moderate. - Altered taste: temporary metallic or bitter taste during treatment, usually subsides after therapy.

Serious or Rare Side Effects: - Clostridioides difficile‑associated diarrhea: severe colitis that may be life‑threatening and require hospitalization. - QT interval prolongation: can lead to cardiac arrhythmias such as torsades, especially with other QT‑prolonging drugs. - Hepatic dysfunction: marked elevation of liver enzymes or hepatitis, occasionally causing jaundice. - Severe allergic reactions: rash, swelling, bronchospasm, or anaphylaxis, requiring immediate medical attention. - Hematologic abnormalities: neutropenia, thrombocytopenia, or other blood disorders that may increase infection risk.

When prescribing Clarithromycin, clinicians should consider several precautionary measures to ensure safe use. - Renal function assessment: adjust dosage in patients with impaired kidney function. - Liver monitoring: evaluate hepatic enzymes before and during therapy. - QT prolongation risk: avoid use with other QT‑prolonging agents or in patients with cardiac arrhythmias. - Hypersensitivity caution: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: use only if benefits outweigh potential risks after professional evaluation. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Clarithromycin can interact with several medicines, altering their effectiveness or safety profile.

Major Interactions (Avoid): - Erythromycin: combined use may increase risk of cardiac toxicity. - Ketoconazole: strong CYP3A4 inhibition can raise clarithromycin levels. - Pimozide: may cause severe QT prolongation and arrhythmias.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Carbamazepine: induces metabolism, potentially reducing clarithromycin efficacy. - Oral contraceptives: may decrease hormonal effectiveness, consider alternative contraception.